Globus Medical risk/reward favorable at current levels, says Leerink Leerink believes the recent pullback in shares of Globus Medical brings a favorable risk/reward profile and long-term buying opportunity. The firm reiterates an Outperform rating on the name.
News For GMED From The Last 14 Days
Check below for free stories on GMED the last two weeks.
Globus Medical downgraded to Hold from Buy at WallachBeth WallachBeth downgraded Globus Medical citing valuation but raised its price target for shares to $27 from $23 following the company's Q4 results.